These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 16923922)

  • 1. Renal and cardiovascular effects of angiotensin-converting enzyme inhibitor plus angiotensin II receptor antagonist therapy in children with proteinuria.
    Lubrano R; Soscia F; Elli M; Ventriglia F; Raggi C; Travasso E; Scateni S; Di Maio V; Versacci P; Masciangelo R; Romero S
    Pediatrics; 2006 Sep; 118(3):e833-8. PubMed ID: 16923922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
    Seeman T; Pohl M; Misselwitz J; John U
    Kidney Blood Press Res; 2009; 32(6):440-4. PubMed ID: 20016211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are two better than one? Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney disease.
    Linas SL
    Clin J Am Soc Nephrol; 2008 Jan; 3 Suppl 1(Suppl 1):S17-23. PubMed ID: 18178792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?
    Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
    J Nephrol; 2007; 20(4):410-6. PubMed ID: 17879206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left ventricular (LV) geometry and dipping state are determinants of LV mass reduction with angiotensin-converting enzyme inhibitor antihypertensive treatment.
    Aznaouridis KA; Vyssoulis GP; Karpanou EA; Marinakis AG; Barbetseas JD; Zervoudaki AI; Cokkinos DV; Stefanadis CI
    Blood Press Monit; 2007 Apr; 12(2):87-94. PubMed ID: 17353651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
    Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
    Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
    Chrysostomou A; Pedagogos E; MacGregor L; Becker GJ
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):256-62. PubMed ID: 17699214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
    Catapano F; Chiodini P; De Nicola L; Minutolo R; Zamboli P; Gallo C; Conte G
    Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there added value to adding ARB to ACE inhibitors in the management of CKD?
    Cohen DL; Townsend RR
    J Am Soc Nephrol; 2009 Aug; 20(8):1666-8. PubMed ID: 18776118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation.
    Jennings DL; Taber DJ
    Ann Pharmacother; 2008 Jan; 42(1):116-20. PubMed ID: 18094340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin blockade as sole treatment for proteinuric kidney disease in children.
    Chandar J; Abitbol C; Montané B; Zilleruelo G
    Nephrol Dial Transplant; 2007 May; 22(5):1332-7. PubMed ID: 17299000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
    Horita Y; Taura K; Taguchi T; Furusu A; Kohno S
    Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How should renin-angiotensin system blockade be applied in chronic kidney disease for optimal renal protection?
    Zhang X; Hou FF
    Chin Med J (Engl); 2007 Feb; 120(3):243-5. PubMed ID: 17355830
    [No Abstract]   [Full Text] [Related]  

  • 19. Acute renal failure during lisinopril and losartan therapy for proteinuria.
    Hanevold CD
    Pharmacotherapy; 2006 Sep; 26(9):1348-51. PubMed ID: 16945058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
    Renke M; Rutkowski P; Tylicki L; Zietkiewicz M; Larczyński W; Rutkowski B
    Przegl Lek; 2008; 65(6):312-4. PubMed ID: 18853664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.